Defunct Company
Total Trials
6
As Lead Sponsor
1
As Collaborator
5
Total Enrollment
285
NCT00613093
Ph. II Temozolomide + O6-BG in Treatment of Pts w Temozolomide-Resistant Malignant Glioma
Phase: Phase 2
Role: Collaborator
Start: Oct 31, 2002
Completion: Aug 31, 2008
NCT00612638
Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas
Phase: Phase 1
Start: Jan 31, 2005
Completion: Jul 31, 2008
NCT00612989
Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM
Start: Feb 28, 2005
NCT00590954
Clinical and Molecular-Metabolic Phase II Trial of Perifosine for Recurrent/Progressive Malignant Gliomas
Start: May 31, 2006
Completion: Nov 11, 2019
NCT00389090
A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma
Role: Lead Sponsor
Start: Oct 31, 2006
Completion: Feb 28, 2009
NCT00873457
Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Start: Aug 31, 2009
Completion: Apr 30, 2013